TipRanks
Go Ultimate55% OFF

Trendlines Group (42T) AI Stock Analysis

Top Page

SG:42T

Trendlines Group

(SGX:42T)

Select Model
Rating:48Neutral
Price Target:SGD 0.05â–²(0.00% Upside)
Action:reiterated
Date:08/17/26

The score is held back primarily by weak cash generation despite the return to reported profitability and a very high P/E valuation. A low-leverage balance sheet and improved TTM earnings/revenue help offset these risks, but technical signals remain soft with the price below major moving averages and a negative MACD.

Positive Factors
Conservative balance sheetLow leverage and a sizable equity base reduce financial risk and provide flexibility for Trendlines to support portfolio companies or absorb periods of uneven investment outcomes. This conservative financing profile is a durable strength because it limits debt-related pressure on capital allocation.
Negative Factors
Weak cash generationNegative operating and free cash flow despite reported net income signals weak earnings conversion and may require reliance on non-cash items or working-capital movements. Persistent cash deficits can constrain Trendlines’ ability to fund portfolio development and reduce financial resilience.

Trendlines Group (42T) vs. iShares MSCI Singapore ETF (EWS)

-30%-20%-10%0%10%20%30%SG:42T-20.97%EWS+12.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
SGD 77.02M
Dividend Yield
―
Average Volume (3M)
686.55K
Price to Earnings (P/E)
6.6
Beta (1Y)
0.45
Revenue Growth
-31.23%
EPS Growth
―
Country
Singapore
Employees
20
Sector
Financial
Sector Strength
68
Industry
Asset Management

Trendlines Group Business Overview & Revenue Model

Company Description

The Trendlines Group Ltd. is a private equity and venture capital firm focused on commercializing innovative technologies. They specialize in early-stage investments, ranging from incubation and seed funding to start-up and even later-stage venture c...

How the Company Makes Money

Trendlines Group generally makes money through a venture-capital/venture-building model tied to its portfolio companies. Key revenue streams typically include: (1) Realized gains from exits: proceeds and profits when portfolio companies are sold, mer...

Trendlines Group Financial Statement Overview

Summary

Mixed fundamentals: TTM shows a rebound to positive net income (~7.3M) and strong revenue growth (~21%), and the balance sheet is conservatively financed with low leverage (debt-to-equity ~0.07) and sizable equity (~84.9M). However, earnings quality is a major concern because operating cash flow and free cash flow are negative in TTM (both ~-8.6M), and profitability has been volatile across years.

Income Statement

56Neutral

Balance Sheet

78Positive

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue14.57M1.99M1.72M4.50M3.58M2.30M
Gross Profit7.31M343.23K-1.73M-793.00K-3.83M-5.04M
EBITDA7.62M2.13M-9.45M-33.93M-16.39M3.95M
Net Income7.30M1.95M-9.43M-33.99M-14.48M6.56M
Balance Sheet
Total Assets91.62M85.76M75.35M78.07M107.99M121.08M
Cash, Cash Equivalents and Short-Term Investments5.01M4.92M5.89M6.11M6.57M18.46M
Total Debt5.32M5.35M4.15M4.64M4.85M10.01M
Total Liabilities6.59M8.45M7.32M9.00M12.10M18.54M
Stockholders Equity84.93M78.26M68.55M70.89M96.99M103.09M
Cash Flow
Free Cash Flow-8.57M-5.89M-8.86M-6.42M-15.04M76.00K
Operating Cash Flow-8.56M-5.87M-8.84M-6.34M-14.93M650.00K
Investing Cash Flow-3.98M-2.38M-948.00K1.92M2.05M-598.00K
Financing Cash Flow10.70M8.09M8.64M5.97M3.13M3.60M

Trendlines Group Technical Analysis

Technical Analysis SentimentNegative
Last Price0.05

Price Trends

50DMA0.05Negative
100DMA0.05Negative
200DMA0.06Negative

Market Momentum

MACD-0.00Negative
RSI40.74Neutral
STOCH120.00Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:42T, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 40.74 is Neutral, neither overbought nor oversold. The STOCH value of 120.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:42T.

Trendlines Group Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

SG:42T against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
SG:42TSG:42T48NeutralSGD 77.02M6.618.95%―-31.23%―
SG:HKBSG:HKB44NeutralSGD 1.92B0.001.40%―10.60%-67.55%

* Financial Sector Average

Performance Comparison

0%100%200%SG:42TSG:5RFSG:CJNSG:HKBSG:I49Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
SG:42T and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SG:42TTrendlines Group 0.05-0.01-18.33%
SG:5RFMercurius Capital Investment Limited0.020.000.00%
SG:CJNBritish and Malayan Holdings Limited2.501.85284.62%
SG:HKBAMTD IDEA Group Class A3.38-0.22-6.11%
SG:I49IFS Capital Ltd.0.15-0.01-3.14%

Trendlines Group Corporate Events

Trendlines Wins SIAS Award for Shareholder Communications Excellence

Oct 25, 2026

Trendlines Group has been named joint winner of the Shareholder Communications Excellence Award in the Small Cap category at the 2026 SIAS Investors’ Choice Awards in Singapore. The accolade recognises the company’s efforts to keep invest...

Trendlines Strengthens Portfolio With U.S. Approvals, Expansion and Final Subscription Installment

Oct 1, 2026

Trendlines completed the second and final installment of a subscription initiated in June 2025, underscoring continued capital structuring for its investment platform. The update highlights active fundraising among its medtech and agrifood portfolio...

EcoPhage Wins EPA Nod for Phage-Based GoldenEco Biopesticide in U.S.

Sep 17, 2026

EcoPhage has secured U.S. Environmental Protection Agency approval for GoldenEco, a phage-based biopesticide targeting destructive bacterial diseases in tomatoes and peppers caused by Xanthomonas and Pseudomonas. The product offers growers a targeted...

Trendlines Group Completes Final Tranche of S$3.49 Million Share Subscription

Sep 8, 2026

Trendlines Group has completed the second and final installment of a previously announced share subscription, issuing 116,420,795 new ordinary shares for gross proceeds of S$3.49 million. Following the allotment of these Second Installment Subscripti...

Trendlines Maintains H1 2026 Profitability as Portfolio Activity Accelerates

Sep 1, 2026

Trendlines Group reported that it remained profitable in the first half of 2026, underscoring steady financial performance and ongoing investor communications through its latest unaudited financials, results release, and August investor presentation....

Trendlines Portfolio Scores U.S. Deals, Patents and EU Project as Fundraising Accelerates

Jul 31, 2026

Trendlines reported a series of portfolio milestones, including ElastiMed securing an exclusive U.S. distribution deal with Nasdaq-listed Tactile Systems Technology Inc. and EcoPhage submitting its fifth product to the U.S. Environmental Protection A...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026